Study of two drugs for Richter transformation lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study tests a combination of two oral drugs (nemtabrutinib and pembrolizumab) for people with Richter transformation, an aggressive lymphoma that develops from chronic lymphocytic leukemia. It may be an option if standard chemotherapy is not suitable or if prior treatment has stopped working.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of lymphoma called Richter transformation (a fast-growing lymphoma that started from CLL or SLL).
- Standard chemotherapy is not an option for you, or your cancer has gotten worse after at least one prior treatment.
- You must be at least 18 years old and able to swallow pills.
- You should be in reasonably good health (able to care for yourself) and have adequate organ function.
- You cannot have had certain immune-based cancer treatments before, or certain other medical conditions like uncontrolled infections or autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two targeted drugs for people with Richter's transformation, an aggressive lymphoma that can develop from CLL. The goal is to see if this combination can help control the disease.
This study tests whether adding a targeted drug called pirtobrutinib to the usual chemotherapy for Richter transformation can improve outcomes. It is a phase 3 trial, meaning it compares the new combination to the standard approach, and may help patients live longer or delay progression.
This trial tests a combination of four drugs for people whose chronic lymphocytic leukemia (CLL) has transformed into a more aggressive lymphoma called Richter syndrome. The goal is to see if this combination can control the cancer and improve outcomes.
This trial tests a new drug called glofitamab combined with standard chemo-immunotherapy (rituximab or obinutuzumab plus CHOP) for people with Richter syndrome, an aggressive lymphoma that arises from CLL. The goal is to see if the combination is safe and effective.
This clinical trial tests two oral medications, nemtabrutinib and venetoclax, given together to people with untreated CLL or SLL. The goal is to see if this combination effectively kills cancer cells and helps you stay in remission with manageable side effects.
This trial tests a drug called glofitamab, alone or combined with other drugs, for people whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has changed into a faster-growing lymphoma (Richter's transformation). The goal is to see how well these treatments work and which combination might be best.
Hear when a new Richter Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.